In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Charles River Laboratories trades above its fair value estimate of $163.31 with a high-confidence implied downside of 13.3%, reflecting potential overvaluation. Weak financial health—zero profitability and efficiency scores—coupled with high Monte Carlo downside risk (80.6%) signals elevated investment risk despite a wide valuation range. Analyst targets and trading multiples suggest market optimism contrasts with fundamental challenges.